• Chat
  • Dashboard
  • Daily Briefing
  • Discover
    • Feedback
    • Sign In
    Sign InSign Up

    Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival - Bloomberg

    AI Summary1 min read

    TL;DR

    Novo Nordisk's new obesity drug CagriSema underperformed against Eli Lilly's Zepbound in a trial, causing Novo's stock to drop 15%.

    Tags

    Novo Nordiskobesity drugEli LillyCagriSemaZepbound
    1. Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival  Bloomberg
    2. Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial  CNBC
    3. Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial  Reuters
    4. Novo Nordisk pitted a new weight-loss drug against Eli Lilly’s — and lost  MarketWatch
    5. Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price  Fierce Biotech

    Monday, February 23, 2026 11:05 AM

    Visit Website
    website-logo

    Top stories - Google News

    Google News

    channel icon
    Related Articles

    As Andrew fell, Queen Elizabeth II held out hope, and Charles and William fumed - The Washington Post

    Feb 23, 2026

    As more Americans embrace anxiety treatment, RFK Jr. derides medications - CBS News

    Feb 23, 2026

    4 years into Russia’s full-scale invasion of Ukraine, a look at the war by the numbers - AP News

    Feb 23, 2026

    Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC

    Feb 23, 2026
    xgithub
    logo

    Copyright © 2022-2026 - Aetos.AI